Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.

Swaathi JayaramanXiaonan HouMary J KuffelVera J SumanTanya L HoskinKathryn E ReinickeDavid G MonroeKrishna R KalariXiaojia TangMegan A ZeldenrustJingfei ChengElizabeth S BruinsmaSarah A BuhrowRenee M McGovernStephanie L SafgrenChad A WaldenJodi M CarterJoel M ReidJames N IngleMatthew M AmesJohn R HawseMatthew P Goetz

Published in: Breast cancer research : BCR (2020)

In endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen results in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy. These data support the ongoing development of Z-endoxifen.

Keyphrases

estrogen receptor
positive breast cancer
type diabetes
randomized controlled trial
machine learning
clinical trial
big data
combination therapy
open label
polycystic ovary syndrome
skeletal muscle
adipose tissue
artificial intelligence
breast cancer cells